Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial

Published:2015-11 Issue:15 Volume:16 Page:1493-1505
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Tournigand Christophe,Chibaudel Benoist,Samson Benoit,Scheithauer Werner,Vernerey Dewi,Mésange Paul,Lledo Gérard,Viret Frédéric,Ramée Jean-François,Tubiana-Mathieu Nicole,Dauba Jérôme,Dupuis Olivier,Rinaldi Yves,Mabro May,Aucoin Nathalie,Latreille Jean,Bonnetain Franck,Louvet Christophe,Larsen Annette K,André Thierry,de Gramont Aimery

Publisher

Elsevier BV

Subject

Oncology

Reference38 articles.

1. Re-challenge and the concept of lines of therapy in metastatic colorectal cancer;de Gramont;Eur J Cancer,2011

2. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial;Heinemann;Lancet Oncol,2014

3. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer;Loupakis;N Engl J Med,2014

4. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial;Adams;Lancet Oncol,2011

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overall survival with non-proportional hazards in first-line treatment for patients with metastatic colorectal cancer: Systematic review and network meta-analysis;Heliyon;2024-08

2. A network meta-analysis of efficacy and safety for first-line and maintenance therapies in patients with unresectable colorectal liver metastases;Frontiers in Pharmacology;2024-07-26

3. Additivity predicts the efficacy of most approved combination therapies for advanced cancer;Nature Cancer;2023-11-16

4. Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements;Frontiers in Oncology;2023-06-20

5. Colorectal cancer: Review of signaling pathways and associated therapeutic strategies;Journal of Surgical Oncology;2023-05-24